
A collaboration between Mayo Clinic researchers and a team dedicated to researching frontotemporal dementia has identified neurofilament light as a useful biomarker for the disease.
“There is at present no truly effective treatment for patients with [frontotemporal dementia (FTD)],” Tania Gendron, PhD, a neuroscientist at the Mayo Clinic and corresponding author of the study, said a Mayo Clinic press release. “It’s believed that potential treatments will be most beneficial to individuals when administered early in the disease course — soon after symptom onset or ideally